Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Consolidated Net Income (2021 - 2025)

SAB Biotherapeutics' Consolidated Net Income history spans 5 years, with the latest figure at -$15.1 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 52.19% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached -$47.8 million, down 46.27%, while the annual FY2025 figure was -$47.8 million, 13.87% down from the prior year.
  • Consolidated Net Income reached -$15.1 million in Q4 2025 per SABSW's latest filing, down from -$12.1 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $1.4 million in Q1 2021 to a low of -$22.9 million in Q4 2023.
  • Average Consolidated Net Income over 5 years is -$7.9 million, with a median of -$7.3 million recorded in 2023.
  • Peak YoY movement for Consolidated Net Income: crashed 845.93% in 2023, then surged 56.5% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then crashed by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then crashed by 52.19% to -$15.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Consolidated Net Income are -$15.1 million (Q4 2025), -$12.1 million (Q3 2025), and -$9.8 million (Q2 2025).